We are a clinical-stage biotechnology company revolutionizing the discovery and development process for novel peptide therapeutics for patients with serious and life-threatening diseases. Combining the untapped potential of peptide biology with the power of machine learning, we strive to scale our drug design approach and usher in the next generation of peptide therapeutics through precision engineering and design. Our lead peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective currently being investigated in clinical studies as a potential treatment for prosthetic joint infection, a historically difficult-to-treat condition with a severe unmet need.